HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target.
Chimera Investment’s Debt Overview
Over the past three months, shares of Chimera Investment Inc. (NYSE:CIM) moved higher by 13.51%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.
